Trials / Terminated
TerminatedNCT00577148
An Efficacy and Safety Study of Rimonabant for Treatment of Nonalcoholic Steatohepatitis (NASH) in Patients With Type 2 Diabetes
A Double-blind, Randomized, Placebo-controlled, Parallel Group Study of Rimonabant 20 mg Daily for the Treatment of Type 2 Diabetic Patients With Nonalcoholic Steatohepatitis (NASH).
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 89 (actual)
- Sponsor
- Sanofi · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the effect of rimonabant treatment on the histological features of Nonalcoholic Steatohepatitis (NASH) in patients with Type 2 diabetes.
Detailed description
The total duration per patient will be approximately 22 months including a 18-month double-blind treatment period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rimonabant | Tablet, oral administration |
| DRUG | Placebo (for Rimonabant) | Tablet, oral administration |
Timeline
- Start date
- 2008-02-01
- Primary completion
- 2009-02-01
- Completion
- 2009-02-01
- First posted
- 2007-12-19
- Last updated
- 2016-05-18
Locations
24 sites across 24 countries: United States, Argentina, Australia, Belgium, Brazil, Chile, China, Colombia, Croatia, France, Germany, Hungary, Italy, Malaysia, Mexico, Philippines, Poland, Portugal, Puerto Rico, Romania, Spain, Switzerland, Taiwan, United Kingdom
Source: ClinicalTrials.gov record NCT00577148. Inclusion in this directory is not an endorsement.